Previous 10 | Next 10 |
Shares of Fluidigm (NASDAQ: FLDM) fell more than 54% on Wednesday after the company reported third-quarter 2019 operating results. The lab instrument developer, supposedly in the midst of a growth spurt, reported that revenue declined compared with the year-ago period. Worse yet, the segme...
Fluidigm (NASDAQ: FLDM ) -31% on Q3 results . More news on: Fluidigm Corporation, Plantronics, Inc., Amneal Pharmaceuticals, Inc., Stocks on the move, Read more ...
The following slide deck was published by Fluidigm Corporation in conjunction with their 2019 Q3 earnings Read more ...
Fluidigm Corporation (FLDM) Q3 2019 Earnings Conference Call November 5, 2019 17:00 ET Company Participants Agnes Lee - VP, IR Chris Linthwaite - President & CEO Vikram Jog - CFO Conference Call Participants Sung Ji Nam - BTIG Dan Brennan - UBS Bill Quirk - Piper Ja...
Fluidigm (NASDAQ: FLDM ): Q3 Non-GAAP EPS of -$0.09 in-line; GAAP EPS of -$0.19 beats by $0.01 . Revenue of $26.5M (-8.5% Y/Y) misses by $2.24M . Press Release More news on: Fluidigm Corporation, Earnings news and commentary, Tech stocks news,
Third quarter revenue decreased 8.5 percent to $26.5 million; year-to-date revenue increased 5 percent to $84.8 million Third quarter consumables revenue increased 11 percent Year-to-date mass cytometry revenue increased 28 percent More than 10 new products commerciali...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced it has exceeded $1 million in revenue from its industry-leading Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Human Immune Monitoring Panel Kit. Use...
ACHC , AINV , AIZ , AKCA , ALRM , ANDE , ATUS , AVLR , BEAT , BTG , CARG , CCRN , CDK , CENX , CGBD , CMP , CNO , COHR , CPSI , CSOD , CWK , CZR , DEI , DVA , DVN , ES , EVH , EVRI , FANG , FATE , FIVN , FLDM , FRGI , FTR , GHL , GPRE , GTE , GTES , GW...
October 21, 2019 Palm Beach, FL – October 21, 2019 – Acute myeloid leukemia (AML) is an orphan’s disease. The FDA defines an orphan’s disease as a condition that affects fewer than 200,000 people nationwide. Before the passage of rare disease laws in th...
Menlo Therapeutics (NASDAQ: MNLO ) initiated with Buy rating and $11 (140% upside) price target at H.C. Wainwright. More news on: Menlo Therapeutics Inc., Dynavax Technologies Corporation, UnitedHealth Group Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...